SKILLMAN, N.J. -- Personal Prod acts, a division of McNeil Consumer, launched a one-dose vaginal yeast infection treatment last month under its Monistat label. Monistat 1 will join the company's Monistat 3 and Monistat 7--three-and seven-day treatments-as well as Bristol-Myers' Vagistat-1, the only other OTC one-dose vaginal yeast treatment on the market, in the feminine health category. However, the active ingredient in Monistat 1 is tioconazole, the same active ingredient used in Vagistat 1. Apparently, the Johnson & Johnson subsidiary has entered into a special licensing agreement with Bristol-Myers, holders of the tioconazole patent. Miconazole is the active ingredient in other Monistat products.
In addition, the company also added a new version of the three-dose treatment, Monistat 3 cream. Both products are to retail in the $16 range.
COPYRIGHT 1998 Reproduced with permission of the copyright holder. Further reproduction or distribution is prohibited without permission.
COPYRIGHT 2004 Gale Group